CDKN2A and breast carcinoma: To date, there have been reports suggesting that p16 may be affected by methylation in primary breast cancers with quoted frequencies of 15–30% [63], [64], [65], [66], [67] and there is a relatively high rate of LOH at 9p21 [68], [69], [63].